Granulocyte-macrophage colony-stimulating factor therapy

Lang E, Cibull ML, Gallicchio VS, Henslee-Downey PJ, Davey DD, Messino MJ, Harder EJ. Proliferation of abnormal bone marrow histiocytes, an undesired effect of granulocyte macrophage-colony-stimulating factor therapy in a patient with Hurler s syndrome undergoing bone marrow transplantation. Am J Hematol 1992 41(4) 280. ... 

Spitler, L.E. et al., Adjuvant therapy of stage HI and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor, J Clin Oncol, 18, 1614, 2000. 

Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CAS, Smithson WA, Burch P, Gornet M, Rahman E (1999), Aerosol granulocyte macrophage-colony stimulating factor a low toxicity, lung-specific biological therapy in patients with lung metastases, Clin. Cancer Res. 5 2316-2323. 

Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J CUn Oncol 1997 15 3496-3506. 

Wadhwa M, Skog A L, Bird C, et al. (1999). Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin. Cancer Res. 5 1353-1361. 

---